𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Involvement of the renin–angiotensin system in the development of vascular damage in a rat model of arthritis: Effect of angiotensin receptor blockers

✍ Scribed by Takeo Sakuta; Yoshitaka Morita; Minoru Satoh; David A. Fox; Naoki Kashihara

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
224 KB
Volume
62
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Renin and angiotensin II receptor expres
Renin and angiotensin II receptor expression in the brains of DES-treated Syrian hamsters
✍ Dodge, Alice H. ;Reid, Ian A. ;Inagami, Tadashi 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 214 KB

Background: The renin angiotensin system (RAS) promotes vasoconstriction. Expression of RAS is induced by different factors. Methods: In this study, forebrain sections of hamster brains were studied by immunohistochemical methods to determine the location of renin-positive and angiotensin II recepto

The pharmacokinetics and metabolism of D
The pharmacokinetics and metabolism of DuP 532, a non-peptide angiotensin II receptor antagonist, in rats and dogs
✍ Y. N. Wong; K. A. Holm; D. L. Burcham; S.-M. Huang; C. Y. Quon 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 481 KB

DuP 532, 2-propy1-4-pentafluoroethyl-l-[ [2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methylJ imidazole-5-carboxylic acid, is an orally active, non-peptide angiotensin I1 (AII) receptor antagonist. DuP 532 is more potent and longer acting than losartan, another A11 receptor antagonist currently undergoing ph

Prevention of vascular damage in sclerod
Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: A multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril
✍ A. E. Gliddon; C. J. Doré; C. M. Black; N. McHugh; R. Moots; C. P. Denton; A. He 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 2 views

## Abstract ## Objective To evaluate the efficacy and tolerability of prolonged administration of quinapril, a long‐acting angiotensin‐converting enzyme inhibitor, in the management of the peripheral vascular manifestations of limited cutaneous systemic sclerosis (lcSSc) and in the prevention of t